ADC Therapeutics (ADCT) EBITDA (2020 - 2026)
ADC Therapeutics (ADCT) posted EBITDA of -$25.2 million for Q1 2026, up 18.48% sequentially from -$31.0 million in Q3 2025, and up 11.31% YoY from -$22.7 million in Q1 2025.
ADC Therapeutics (ADCT) EBITDA (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported EBITDA for 7 years, with the latest figure at -$25.2 million in Q1 2026.
- Quarterly EBITDA rose 11.31% year-over-year to -$25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$128.8 million (down 1.69% YoY) and the FY2022 annual result came in at -$21.4 million, up 89.91% from the prior year.
- EBITDA grew to -$25.2 million in Q1 2026 per ADCT's latest filing, from -$31.0 million in the prior quarter.
- Over five years, EBITDA peaked at -$3.1 million in Q3 2022 and troughed at -$69.4 million in Q2 2022.
- A 5-year average of -$34.4 million and a median of -$34.6 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA jumped 94.61% in 2022, then slumped 1060.85% in 2023.
- Over 5 years, EBITDA stood at -$14.9 million in 2022, then slumped by 142.63% to -$36.1 million in 2023, then climbed by 1.62% to -$35.6 million in 2024, then rose by 12.92% to -$31.0 million in 2025, then rose by 18.48% to -$25.2 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$25.2 million, -$31.0 million, and -$44.1 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | ADC Therapeutics | 148.95 Mn | -70.15 Mn | 17.14 Mn | -25.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.41 Mn |
| Mar 31, 2026 | -25.25 Mn |
| Sep 30, 2025 | -30.97 Mn |
| Jun 30, 2025 | -44.15 Mn |
| Mar 31, 2025 | -28.46 Mn |
| Sep 30, 2024 | -35.56 Mn |
| Jun 30, 2024 | -29.04 Mn |
| Mar 31, 2024 | -33.61 Mn |
| Sep 30, 2023 | -36.15 Mn |
| Jun 30, 2023 | -39.65 Mn |
| Mar 31, 2023 | -51.57 Mn |
| Dec 31, 2022 | -14.90 Mn |
| Sep 30, 2022 | -3.11 Mn |
| Jun 30, 2022 | -69.41 Mn |
| Mar 31, 2022 | -40.36 Mn |
| Dec 31, 2021 | -26.00 Mn |
| Sep 30, 2021 | -57.79 Mn |
| Jun 30, 2021 | -70.48 Mn |
| Mar 31, 2021 | -70.67 Mn |
| Dec 31, 2020 | -54.21 Mn |